Novavax’s Covid-19 vaccine shows early signs of promise
The latest beat in the metronomic release of early-stage Covid-19 vaccine data came yesterday from Novavax, whose investigational injection led to a promising immune response with mostly mild side effects.
The data, from about 130 healthy volunteers, demonstrated a substantial increase in neutralizing antibodies after 35 days. Novavax tested four escalating doses of its vaccine and found that the two highest doses, administered 21 days apart with an adjuvant, led to an average level of neutralizing antibodies that was about four times what was seen in patients who had recovered from Covid-19.
Experts offered the familiar caution that, while these results offer preliminary promise, there’s no way to know whether any vaccine, Novavax’s or otherwise, is effective until we have data from large-scale trials. Novavax plans to enter Phase 3 this fall, a few months behind competitors Moderna, AstraZeneca, and the partnership of Pfizer and BioNTech.
Read more.
The data, from about 130 healthy volunteers, demonstrated a substantial increase in neutralizing antibodies after 35 days. Novavax tested four escalating doses of its vaccine and found that the two highest doses, administered 21 days apart with an adjuvant, led to an average level of neutralizing antibodies that was about four times what was seen in patients who had recovered from Covid-19.
Experts offered the familiar caution that, while these results offer preliminary promise, there’s no way to know whether any vaccine, Novavax’s or otherwise, is effective until we have data from large-scale trials. Novavax plans to enter Phase 3 this fall, a few months behind competitors Moderna, AstraZeneca, and the partnership of Pfizer and BioNTech.
Read more.
.png)
No hay comentarios:
Publicar un comentario